ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: ABT-888 may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth. Collecting and storing samples of blood from patients with cancer to study
in the laboratory may help doctors learn more about the ways a patient's body handles the
drug.
PURPOSE: This early phase I trial is studying the side effects and best dose of ABT-888 in
patients with refractory solid tumors or hematologic cancer.
Phase:
Phase 1
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)